• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    3/10/23 4:36:22 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    SC 13G/A 1 upix_sc13g.htm SC 13G/A upix_sc13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    § 240.13d-1(b), (c), and (d) and AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

     

    (Amendment No. 1)*

     

    UPEXI, INC.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    39959A106

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

     

     

     

    ☐

    Rule 13d-1(c)

     

     

     

     

    ☒

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 2 of 6 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Gene Salkind (1)

     

     

    2

    .

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    94,444 (2)

    6.

    SHARED VOTING POWER

     

    2,352,941 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    94,444 (2)

    8.

    SHARED DISPOSITIVE POWER

     

    2,352,941 (1)

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,447,385 (1) (2)

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    (SEE INSTRUCTIONS)

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    13.56% (3)

     

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

    (1) Includes shares of Common Stock of the Issuer titled Gene and Catherine Salkind as joint tendency with survivor rights.

     

    (2) Includes options for the purchase of 94,444 of the Issuer’s Common Stock exercisable within 60 days.

     

    (3) Based on 17,960,748 shares of Common Stock as reported in the Issuer’s quarterly report as filed with the Commission on February 15, 2023, and 94,444 shares of the Issuer’s Common Stock issuable upon the exercise of options.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 3 of 6 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Catherine Salkind (1)

     

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    2,352,941 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    2,352,941 (1)

     

     9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,352,941

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    (SEE INSTRUCTIONS)

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    13.1% (2)

     

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

    (1) Includes shares of Common Stock of the Issuer titled Gene and Catherine Salkind as joint tenancy with survivor rights.

     

    (2) Based on 17,960,748 shares of Common Stock as reported in the Issuer’s quarterly report as filed with the Commission on February 15, 2023.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 4 of 6 Pages

     

    Item 1.

     

     

     

     

     

     

    (a)

    Name of Issuer: Upexi, Inc.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices:

     

    17129 US Hwy 19 N.

    Clearwater, FL 33764

     

    Item 2.

     

     

     

     

     

     

    (a)

    Name of Person Filing: Gene and Catherine Salkind

     

     

     

     

    (b)

    Address of Principal Business Office or, if none, Residence:

     

    17129 US Hwy 19 N.

    Clearwater, FL 33764

     

     

    (c)

    Citizenship or Place of Organization: United States of America

     

     

     

     

    (d)

    Title of Class of Securities: Common Stock

     

     

     

     

    (e)

    CUSIP Number: 39959A106

     

    Item 3.

    If this statement is filed pursuant to § 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)

    ☐

    Broker or dealer registered under Section 15 of the Act.

     

     

     

     

     

    (b)

    ☐

    Bank as defined in Section 3(a)(6) of the Act.

     

     

     

     

     

    (c)

    ☐

    Insurance company as defined in Section 3(a)(19) of the Act.

     

     

     

     

     

    (d)

    ☐

    Investment company registered under Section 8 of the Investment Company Act of 1940.

     

     

     

     

     

    (e)

    ☐

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ☐

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

     

     

     

     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

     

     

     

     

    (j)

    ☐

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

     

     

     

     

    (k)

    ☐

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________________.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 5 of 6 Pages

     

    Item 4.

    Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

    (a)

    Amount beneficially owned:

    Gene Salkind  2,447,385

     

     

    Catherine Salkind  2,352,941

     

     

     

     

    (b)

    Percent of class:

    Gene Salkind  13.56%

    Catherine Salkind  13.1%

     

     

     

     

    (c)

    Number of shares as to which the person has:

     

     

    (i)

    Sole power to vote or to direct the vote:

    Gene Salkind 94,444

     

     

     

     

    (ii)

    Shared power to vote or to direct the vote:

    Gene Salkind 2,352,941

    Catherine Salkind 2,352,941

     

     

     

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    Gene Salkind 94,444

     

     

     

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    Gene Salkind 2,352,941

    Catherine Salkind 2,352,941

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

     Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security

     

    Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.

    Certifications.

     

    Not Applicable.

     

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    March 10, 2023

     

    (Date)

     

     

     

    /s/ Gene Salkind

     

    (Signature)

     

     

     

    Gene Salkind

     

    (Name/Title)

     

     

    March 7, 2023

     

    (Date)

     

     

     

    /s/ Catherine Salkind

     

    (Signature)

     

     

     

    Catherine Salkind

     

    (Name/Title)

     

    Attention: Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

     

    Get the next $UPXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/23/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-1 filed by Upexi Inc.

      S-1 - UPEXI, INC. (0001775194) (Filer)

      5/22/25 5:04:41 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/16/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BitGo and Upexi Announce Strategic Partnership to Secure Digital Asset Treasury Holdings

      BitGo, the leading infrastructure provider of digital asset solutions, today announced a strategic partnership with Upexi Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. Under this partnership, Upexi will leverage BitGo's secure custodial and over-the-counter (OTC) trading services to manage its growing digital asset portfolio. This move builds on Upexi's recent announcement that it has increased its Solana (SOL) treasury holdings to over 595,000 tokens, valued at approximately $100 million at current value, and has begun generating staking revenue as part of its broad

      5/13/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

      DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that it has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, which was effective as of October 16, 2024. This decision follows a comprehensive review of highly irregular trading patterns and an unprecedented increase in the number of shareholder accounts, factors that collectively raise concerns about potential stock manipulation. This investigation also follows a recent r

      12/4/24 7:00:00 AM ET
      $MGRX
      $UPXI
      Misc Health and Biotechnology Services
      Health Care
      Medicinal Chemicals and Botanical Products

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care